Lastly, although mesothelin targeted therapeutics have in general shown limited off‐tumour‐on‐target toxicity in clinical trials,30 it is a concern for highly active CAR T cells that can recognise low level mesothelin expression on normal tissues. The gene discussed is MSLN; the disease is neoplasm.